5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex |
| |
| Authors: | Lacroix Laurent P Dawson Lee A Hagan Jim J Heidbreder Christian A |
| |
| Institution: | Centre of Excellence for Drug Discovery in Psychiatry, Department of Biology, GlaxoSmithKline Pharmaceuticals, 37135 Verona, Italy, and Harlow, CM19 5AW, UK. laurent.p.lacroix@gsk.com |
| |
| Abstract: | The present study investigated the neurochemical effects of the selective 5-HT(6) receptor antagonist SB-271046 in the rat medial prefrontal cortex (mPFC). The effect of SB-271046 on extracellular levels of dopamine (DA), norepinephrine (NE), and serotonin (5-HT) in the mPFC was examined using in vivo microdialysis in the freely moving rat. SB-271046 (10 mg/kg, p.o.) produced a significant increase in extracellular levels of both DA and NE without altering 5-HT neurotransmission. These results further support the rationale for the use of 5-HT(6) receptor antagonists in the treatment of cognitive dysfunction associated with psychiatric diseases. |
| |
| Keywords: | 5‐HT6 receptor dopamine medial prefrontal cortex microdialysis norepinephrine SB‐271046 serotonin |
| 本文献已被 PubMed 等数据库收录！ |
|
